ArticleiScience2026
Integrated multi-omics profiling of gut microbiome and metabolome in ulcerative colitis insights from the Iranian population.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Multi-Omics Reveals Complementary Luminal and Mucosal Host-Microbiome Interactions Associated with Disease Activity and Phenotype in Paediatric Inflammatory Bowel Disease.Microorganisms · 2026Article
- Fecal calprotectin and gut microbiome in a cohort without intestinal pathologies from northern Italy.iScience · 2026Article
- Personalized Medicine, Storied Past, Contentious Present, Promising Future.Journal of personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is a chronic inflammatory disorder of the gastrointestinal tract associated with substantial alterations in gut microbial composition and metabolic function. This study investigated intestinal dysbiosis in affected individuals using microbial profiling, genetic analysis, metabolomic assessment, and pathway modeling. Patients showed reduced microbial diversity, loss of beneficial species such as Faecalibacterium and Roseburia, and increased abundance of inflammatory taxa, including Escherichia coli and Fusobacterium, alongside a marked decrease in the Firmicutes-to-Bacteroidetes ratio. Levels of key short-chain fatty acids, particularly butyrate, and protective metabolites such as indole-3-propionic acid were diminished, whereas pro-inflammatory metabolites, including sphingosine, were elevated. Pathway analysis indicated disruptions in tryptophan metabolism and short-chain fatty acid biosynthesis, and species-metabolite networks highlighted antagonistic relationships between inflammatory bacteria and protective metabolites. These findings reveal extensive structural and functional dysbiosis and underscore the potential of microbiome-based therapeutic strategies for managing ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.